340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

التفاصيل البيبلوغرافية
العنوان:	340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
المؤلفون:	Ben Tran, Nabil Adra, Jean-Pascal Machiels, Sylvie Rottey, Tanya Dorff, Lisa Horvath, Matthew Rettig, Martijn Lolkema, Karen Autio, Richard Greil, Shirley Poon, Daniel Tan, Gabor Jurida, Hosein Kouros-Mehr
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
بيانات النشر:	BMJ Publishing Group, 2020.
سنة النشر:	2020
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2051-1426
Relation:	https://doaj.org/toc/2051-1426
DOI:	10.1136/jitc-2020-SITC2020.0340
URL الوصول:	https://doaj.org/article/adaacf7cb04b45f685d2be6482fb3256
رقم الأكسشن:	edsdoj.f7cb04b45f685d2be6482fb3256
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2020-SITC2020.0340